Novel oncologic therapy response criteria (iRECIST and more) - Mint Medical GmbH
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics - The Lancet Oncology
soria on Twitter: "#ENA2016 Dr seymour @theNCI @EORTC @aacr on iRECIST goals and limitations https://t.co/2TBUcpcndq" / Twitter
Statistical Analysis Plan Title: A Phase 1/2, Multicenter, Single-Arm, Open-Label, Dose-Escalation Study of Birinapant in Combin
How to better understand iRECIST – a new wave in immunotherapeutic
Novel oncologic therapy response criteria (iRECIST and more) - Mint Medical GmbH
Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis | Journal for ImmunoTherapy of Cancer
PDF) Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis
CDISC Compliant Implementation of iRECIST and LYRIC for Immunomodulatory Therapy Trials
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. - Abstract - Europe PMC
The Radiology Assistant : RECIST 1.1 - and more
How to better understand iRECIST – a new wave in immunotherapeutic
Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis | Journal for ImmunoTherapy of Cancer
Assessing Immunotherapy Response and Progression
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics - ScienceDirect
The Radiology Assistant : RECIST 1.1 - and more
The Radiology Assistant : RECIST 1.1 - and more
Response evaluation for immunotherapy through semi-automatic software based on RECIST 1.1, irRC, and iRECIST criteria: comparison with subjective assessment - Ying-Chieh Lai, Wen-Cheng Chang, Chun-Bing Chen, Chi-Liang Wang, Yu-Fen Lin, Ming-Mo Ho,
iRECIST: how to do it | Cancer Imaging | Full Text
Response Criteria in Oncologic Imaging: Review of Traditional and New Criteria | RadioGraphics
PDF) Comparison of RECIST 1.1 and iRECIST in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
PDF) RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: The GERCOR NIPICOL phase II study
Paper Template
